A Phase II Neo-adjuvant Study Assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in HER-2 Positive Breast Cancer Patients.
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Docetaxel, Carboplatin and Trastuzumab|DRUG: Docetaxel, Carboplatin, Trastuzumab and Lapatinib
Sponsor: Cancer Trials Ireland